Professor Bryan Williams received his PhD from the Department of Microbiology at the University of Otago, Dunedin, New Zealand. Following postdoctoral training at the National Institute for Medical Research, Mill Hill, London, he held faculty positions at the University of Toronto and the Hospital for Sick Children, Toronto, Canada. He was Chairman of the Department of Cancer Biology at the Lerner Research Institute, Cleveland Clinic, USA, before joining the Monash Institute of Medical Research (MIMR) as Director. He is currently Director and CEO of the Hudson Institute of Medical Research, created by the merging of MIMR with Prince Henry’s Institute.
Professor Williams is a distinguished researcher and international authority on innate immunity and cancer biology. He has made major contributions to our understanding of the antiviral mechanisms of actions of interferons, advancing their therapeutic utility. His discoveries in the 2-5A-RNaseL pathway, cloning and characterisation of protein kinase R, and innate immune signalling pathways have opened new therapeutic opportunities.
Professor Williams is an Honorary Fellow of the Royal Society of New Zealand. He is a Fellow of the American Academy of Microbiology and a Fellow of the Australian Academy of Science.